QNCX (STOCKS)
Quince Therapeutics, Inc. Common Stock
$1.170000
-0.240000 (-17.02%)
Prev close: $1.410000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Dirk Thye
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $6.96M
- Employees
- 36
- P/E (TTM)
- -0.08
- P/B (TTM)
- -0.20
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
0
Strong Buy
0
Buy
5
Hold
2
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-7.10 | $-1.93 | -5.1742 | -268.68% |
|
Sep 2025 (Q3)
|
$-2.50 | $-2.21 | -0.2927 | -13.26% |
|
Jun 2025 (Q2)
|
$-0.23 | $-0.26 | +0.0267 | +10.40% |
|
Mar 2025 (Q1)
|
$-0.34 | $-0.23 | -0.1079 | -46.49% |
Financial Statements
| Revenues | $0.00 |
| Operating Expenses | $58.07M |
| Depreciation and Amortization | $142.00K |
| Research and Development | $35.38M |
| Other Operating Expenses | $22.54M |
| Operating Income/Loss | -$58.07M |
| Income/Loss From Continuing Operations After Tax | -$83.98M |
| Income/Loss From Continuing Operations Before Tax | -$80.77M |
| Income Tax Expense/Benefit | $3.21M |
| Income Tax Expense/Benefit, Current | $8.80M |
| Income Tax Expense/Benefit, Deferred | -$5.59M |
| Net Income/Loss | -$80.77M |
| Net Income/Loss Attributable To Noncontrolling Interest | $3.21M |
| Net Income/Loss Attributable To Parent | -$83.98M |
| Net Income/Loss Available To Common Stockholders, Basic | -$83.98M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.68 |
| Diluted Earnings Per Share | -$1.68 |
| Basic Average Shares | 50,096,897 |
| Diluted Average Shares | 50,096,897 |
| Assets | $93.52M |
| Current Assets | $22.90M |
| Cash | $17.80M |
| Prepaid Expenses | $255.00K |
| Other Current Assets | $4.84M |
| Noncurrent Assets | $70.63M |
| Fixed Assets | $595.00K |
| Intangible Assets | $67.82M |
| Other Non-current Assets | $2.21M |
| Liabilities | $129.24M |
| Current Liabilities | $43.23M |
| Accounts Payable | $2.22M |
| Other Current Liabilities | $41.00M |
| Noncurrent Liabilities | $86.01M |
| Long-term Debt | $0.00 |
| Equity | -$35.71M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | -$35.71M |
| Liabilities And Equity | $93.52M |
| Net Cash Flow From Operating Activities | -$41.43M |
| Net Cash Flow From Operating Activities, Continuing | -$41.43M |
| Net Cash Flow From Investing Activities | $23.23M |
| Net Cash Flow From Investing Activities, Continuing | $23.23M |
| Net Cash Flow From Financing Activities | $17.91M |
| Net Cash Flow From Financing Activities, Continuing | $17.91M |
| Exchange Gains/Losses | -$114.00K |
| Net Cash Flow | -$403.00K |
| Net Cash Flow, Continuing | -$289.00K |
| Comprehensive Income/Loss | -$78.19M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$78.19M |
| Other Comprehensive Income/Loss | $2.57M |